CRISPR Therapeutics AG (CRSP) vs Erasca, Inc. (ERAS)
CRISPR Therapeutics AG and Erasca, Inc. are both Biotechnology companies. CRISPR Therapeutics AG and Erasca, Inc. are of similar size ($5.4B and $5.1B). Erasca, Inc. has the higher net margin (0.00% vs −3,368.7%) and the lower return on invested capital (−203.1% vs 0.00%). Across the 14 metrics below, Erasca, Inc. leads on 8 and CRISPR Therapeutics AG on 6.
Valuation
Profitability
| Metric | CRSP | ERAS | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 0.00% | 65.16% |
| Operating margin | (3,989.99%) | 0.00% | 0.00% |
| Net margin | (3,368.72%) | 0.00% | 0.00% |
| Free cash flow margin | (2,772.74%) | 0.00% | 0.00% |
| Return on equity | (26.09%) | (78.25%) | (57.72%) |
| Return on assets | (19.28%) | (65.25%) | (49.22%) |
| Return on invested capital | 0.00% | (203.13%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack